

ACADIA PHARMACEUTICALS INC  
Form 8-K  
March 18, 2016

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 15, 2016

Commission File Number: 000-50768

ACADIA Pharmaceuticals Inc.  
(Exact name of registrant as specified in its charter.)

Delaware  
(State or other jurisdiction of incorporation or organization)  
061376651  
(IRS Employer Identification No.)

3611 Valley Centre Drive, Suite 300, San Diego, California 92130  
(Address of principal executive offices)

858-558-2871  
(Registrant's Telephone number)

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On March 15, 2016, the Board of Directors of ACADIA Pharmaceuticals Inc. adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2016. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

Date: *March 18, 2016*

By: */s/ Glenn F. Baity*

---

*Name: Glenn F. Baity*

*Title: EVP, General Counsel & Secretary*

---

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Description of Executive Officer Annual Incentive Cash Compensation Program